huib ovaa
huib ovaa
lumc and leiden university
Verified email at lumc.nl - Homepage
Title
Cited by
Cited by
Year
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan, L Catley, G Li, K Podar, T Hideshima, M Velankar, ...
Cancer cell 8 (5), 407-419, 2005
7652005
Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family
A Borodovsky, H Ovaa, N Kolli, T Gan-Erdene, KD Wilkinson, HL Ploegh, ...
Chemistry & biology 9 (10), 1149-1159, 2002
5432002
Generation of peptide–MHC class I complexes through UV-mediated ligand exchange
B Rodenko, M Toebes, SR Hadrup, WJE Van Esch, AM Molenaar, ...
Nature protocols 1 (3), 1120, 2006
5132006
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll, CR Berkers, HL Ploegh, H Ovaa
Structure 14 (3), 451-456, 2006
4822006
OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis
TET Mevissen, MK Hospenthal, PP Geurink, PR Elliott, M Akutsu, ...
Cell 154 (1), 169-184, 2013
3802013
Design and use of conditional MHC class I ligands
M Toebes, M Coccoris, A Bins, B Rodenko, R Gomez, NJ Nieuwkoop, ...
Nature medicine 12 (2), 246-251, 2006
3422006
Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2
E Meulmeester, MM Maurice, C Boutell, AFAS Teunisse, H Ovaa, ...
Molecular cell 18 (5), 565-576, 2005
2982005
Disease-associated prion protein oligomers inhibit the 26S proteasome
M Kristiansen, P Deriziotis, DE Dimcheff, GS Jackson, H Ovaa, ...
Molecular cell 26 (2), 175-188, 2007
2872007
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
R Piva, B Ruggeri, M Williams, G Costa, I Tamagno, D Ferrero, V Giai, ...
Blood, The Journal of the American Society of Hematology 111 (5), 2765-2775, 2008
2832008
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin
B Pang, X Qiao, L Janssen, A Velds, T Groothuis, R Kerkhoven, ...
Nature communications 4 (1), 1-13, 2013
2792013
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib
CR Berkers, M Verdoes, E Lichtman, E Fiebiger, BM Kessler, ...
Nature methods 2 (5), 357-362, 2005
2732005
Structural basis of substrate discrimination and integrin binding by autotaxin
J Hausmann, S Kamtekar, E Christodoulou, JE Day, T Wu, Z Fulkerson, ...
Nature structural & molecular biology 18 (2), 198-204, 2011
2652011
Differential dependence of CD4+ CD25+ regulatory and natural killer-like T cells on signals leading to NF-κB activation
M Schmidt-Supprian, J Tian, EP Grant, M Pasparakis, R Maehr, H Ovaa, ...
Proceedings of the National Academy of Sciences 101 (13), 4566-4571, 2004
2592004
Chemical synthesis of ubiquitin, ubiquitin‐based probes, and diubiquitin
F El Oualid, R Merkx, R Ekkebus, DS Hameed, JJ Smit, A de Jong, ...
Angewandte Chemie International Edition 49 (52), 10149-10153, 2010
2502010
Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity
PC Evans, H Ovaa, M Hamon, PJ Kilshaw, S Hamm, S Bauer, HL Ploegh, ...
Biochemical Journal 378 (3), 727-734, 2004
2502004
On terminal alkynes that can react with active-site cysteine nucleophiles in proteases
R Ekkebus, SI van Kasteren, Y Kulathu, A Scholten, I Berlin, PP Geurink, ...
Journal of the American Chemical Society 135 (8), 2867-2870, 2013
2262013
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity
J van Loosdregt, V Fleskens, J Fu, AB Brenkman, CPJ Bekker, ...
Immunity 39 (2), 259-271, 2013
2112013
Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins
J Hemelaar, A Borodovsky, BM Kessler, D Reverter, J Cook, N Kolli, ...
Molecular and cellular biology 24 (1), 84-95, 2004
2092004
Chemistry in living cells: detection of active proteasomes by a two‐step labeling strategy
H Ovaa, PF Van Swieten, BM Kessler, MA Leeuwenburgh, E Fiebiger, ...
Angewandte Chemie 115 (31), 3754-3757, 2003
2022003
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials
B C Potts, M X Albitar, K C Anderson, S Baritaki, C Berkers, B Bonavida, ...
Current cancer drug targets 11 (3), 254-284, 2011
2002011
The system can't perform the operation now. Try again later.
Articles 1–20